Investors & Media

Transformative science, targeted medicines

Blueprint Medicines is a fully integrated global biopharmaceutical company that invents life-changing medicines across two strategic focus areas of allergy/inflammation and oncology/hematology. Our approach combines deep scientific expertise, modality-agnostic drug discovery capabilities, and a proven track record of R&D success. Currently, we are commercializing our approved medicine AYVAKIT/AYVAKYT® (avapritinib) in the U.S. and Europe, as well as in other regions of the world through partnerships.

SEC Filings

SEC Filings

Search
Filing date Form Description View
S-8

Securities offered to employees pursuant to employee benefit plans

 View HTML
0001104659-23-023067.pdf
0001104659-23-023067.rtf
0001104659-23-023067.xls
S-8

Securities offered to employees pursuant to employee benefit plans

 View HTML
0001104659-24-024937.pdf
0001104659-24-024937.rtf
0001104659-24-024937.xls
S-3ASR

S-3ASR

 View HTML
0001558370-17-001548.pdf
0001558370-17-001548.rtf
0001558370-17-001548.xls
S-3ASR

S-3ASR

 View HTML
0001558370-20-000789.pdf
0001558370-20-000789.rtf
0001558370-20-000789.xls
S-3ASR

S-3ASR

 View HTML
0001104659-23-023051.pdf
0001104659-23-023051.rtf
0001104659-23-023051.xls
S-3/A

Pre-effective amendment to an S-3 filing

 View HTML
0001558370-16-006734.pdf
0001558370-16-006734.rtf
0001558370-16-006734.xls
S-3

Simplified registration form

 View HTML
0001558370-16-005826.pdf
0001558370-16-005826.rtf
0001558370-16-005826.xls
S-1MEF

Registration of up to an additional 20% of securities for any offering registered on an S-1

 View HTML
0001104659-15-031752.pdf
0001104659-15-031752.rtf
0001104659-15-031752.xls
S-1/A

Amended Registration statement for face-amount certificate companies

 View HTML
0001047469-15-003351.pdf
0001047469-15-003351.rtf
0001047469-15-003351.xls
S-1/A

Amended Registration statement for face-amount certificate companies

 View HTML
0001047469-15-003668.pdf
0001047469-15-003668.rtf
0001047469-15-003668.xls